HHS funds vaccine candidates for Marburg, Sudan ebolavirus
The Department of Health and Human Services yesterday awarded $20.5 million to develop vaccine candidates for Marburg virus and Sudan ebolavirus, which are in the same family of viruses as the Ebola virus outbreak in the Democratic Republic of the Congo. The last outbreaks of Marburg virus and Sudan ebolavirus were in Uganda, in 2017 and 2012, respectively. The Sabin Vaccine Institute will conduct nonclinical studies and complete manufacturing activities to advance the development of the vaccine candidates under a contract with HHS’s Biomedical Advanced Research and Development Authority. BARDA also is helping to develop and procure vaccines, therapeutics and diagnostics for the Ebola strain circulating in the Congo.
Related News Articles
Headline
The Food and Drug Administration May 16 announced it cleared the first blood test to diagnose Alzheimer’s disease. The test, created by Fujirebio Diagnostics,…
Headline
The National Institutes of Health May 8 released an analysis that found incidences of 14 types of cancer increased among people under age 50 from 2010-2019.…
Headline
A New England Journal of Medicine study published yesterday found success in administering dostarlimab, an immunotherapy drug, to a group of 103 cancer…
Headline
Overall cancer death rates declined steadily among both men and women from 2018 through 2022, according to the National Institutes of Health's latest annual…
Headline
A study published April 14 by JAMA Network Open found that rates of pancreatic and colon cancer rose among young adults from 2000-2021. Researchers examined…
Headline
The Centers for Medicare & Medicaid Services April 10 released key priorities for new CMS Administrator Mehmet Oz, who was confirmed to the position April…